Original Articles
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Feb 7, 2009; 15(5): 561-569
Published online Feb 7, 2009. doi: 10.3748/wjg.15.561
Figure 4
Figure 4 Effects of different doses of Tat-NBD (WT) in IL-1β protein expression of AR42J by ELISA. TAT-NBD (WT) decreased IL-1β protein in a dose-dependent fashion over a range of 0.1 to 100 mg/L. Control: Cells were incubated with buffer control (n = 3); LPS: Cells were stimulated by LPS for 2 h (n = 3). 0.1: Pretreatment with 0.1 mg/L of Tat-NBD (WT) (n = 3); 1: Pretreatment with 1 mg/L of Tat-NBD (WT) (n = 3); 10: Pretreatment with 10 mg/L of Tat-NBD (WT) (n = 3); 100: Pretreatment with 100 mg/L of Tat-NBD (WT) (n = 3). aP < 0.05, bP < 0.01, vs LPS group. dP < 0.01 vs LPS group.